Paper25344762
Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.
Li H and 10 others. Cancer Chemother Pharmacol, 2014. Cited by 64 papers, by iCite.
Cite this record
ConductScience Library. Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression. Papers, record 25344762. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25344762
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Vascular Endothelial Growth Factor A | Major topic |
| Animals | |
| Antibodies, Monoclonal, Humanized | |
| Bevacizumab | |
| Cell Line, Tumor | |
| Chromatography, High Pressure Liquid | |
| Drug Resistance, Neoplasm | |
| Enzyme-Linked Immunosorbent Assay | |
| ErbB Receptors | |
| Erlotinib Hydrochloride | |
| Female | |
| Humans | |
| Mice | |
| Mice, Inbred BALB C | |
| Mice, Nude | |
| Quinazolines | |
| Xenograft Model Antitumor Assays |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02704767 | Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma | Background |
Source ClinicalTrials.gov
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16079312 | FDA drug approval summary: erlotinib (Tarceva) tablets. | Oncologist | 2005 | https://conductscience.org/library/papers/16079312 | PubMed |
| 2 | 17602060 | FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. | Oncologist | 2007 | https://conductscience.org/library/papers/17602060 | PubMed |
| 3 | 10525095 | Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. | J Pharmacol Exp Ther | 1999 | https://conductscience.org/library/papers/10525095 | PubMed |
| 4 | 9354447 | Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. | Cancer Res | 1997 | https://conductscience.org/library/papers/9354447 | PubMed |
| 5 | 21296855 | Global cancer statistics. | CA Cancer J Clin | 2011 | https://conductscience.org/library/papers/21296855 | PubMed |
| 6 | 23594426 | Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. | J Natl Cancer Inst | 2013 | https://conductscience.org/library/papers/23594426 | PubMed |
| 7 | 17024232 | Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application. | Cancer Gene Ther | 2007 | https://conductscience.org/library/papers/17024232 | PubMed |
| 8 | 23468851 | EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. | PLoS One | 2013 | https://conductscience.org/library/papers/23468851 | PubMed |
| 9 | 11506500 | Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. | Br J Cancer | 2001 | https://conductscience.org/library/papers/11506500 | PubMed |
| 10 | 21592673 | Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. | Cancer Treat Rev | 2012 | https://conductscience.org/library/papers/21592673 | PubMed |
| 11 | 9377574 | Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. | Cancer Res | 1997 | https://conductscience.org/library/papers/9377574 | PubMed |
| 12 | 23335047 | Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. | Int J Cancer | 2013 | https://conductscience.org/library/papers/23335047 | PubMed |
| 13 | 23335087 | Cancer statistics, 2013. | CA Cancer J Clin | 2013 | https://conductscience.org/library/papers/23335087 | PubMed |
| 14 | 16362295 | Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. | Cancer Chemother Pharmacol | 2006 | https://conductscience.org/library/papers/16362295 | PubMed |
| 15 | 17888036 | Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. | Cancer Sci | 2007 | https://conductscience.org/library/papers/17888036 | PubMed |
| 16 | 23953842 | Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. | Biomaterials | 2013 | https://conductscience.org/library/papers/23953842 | PubMed |
| 17 | 20729074 | Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment. | Eur J Cancer | 2010 | https://conductscience.org/library/papers/20729074 | PubMed |
| 18 | 17374728 | The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. | Mol Cancer Res | 2007 | https://conductscience.org/library/papers/17374728 | PubMed |
| 19 | 18596824 | VEGF-targeted therapy: mechanisms of anti-tumour activity. | Nat Rev Cancer | 2008 | https://conductscience.org/library/papers/18596824 | PubMed |
| 20 | 21629292 | Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. | Nat Rev Drug Discov | 2011 | https://conductscience.org/library/papers/21629292 | PubMed |
Cited by46
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 64 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41701619 | TRIPODD Enables Single-Cell Quantification of Therapeutic Efficacy. | Mol Pharm | 2026 | https://conductscience.org/library/papers/41701619 | PubMed |
| 40843133 | VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/40843133 | PubMed |
| 37873790 | Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis. | Diseases | 2023 | https://conductscience.org/library/papers/37873790 | PubMed |
| 37817767 | Pre-clinical lung squamous cell carcinoma mouse models to identify novel biomarkers and therapeutic interventions. | Front Oncol | 2023 | https://conductscience.org/library/papers/37817767 | PubMed |
| 37698765 | Modern therapies of nonsmall cell lung cancer. | J Appl Genet | 2023 | https://conductscience.org/library/papers/37698765 | PubMed |
| 37427337 | A retrospective study of the efficacy of combined EGFR‑TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR‑TKI monotherapy for PD‑L1‑positive EGFR‑mutant non‑small cell lung cancer: North Japan Lung Cancer Study Group 2202. | Oncol Lett | 2023 | https://conductscience.org/library/papers/37427337 | PubMed |
| 36945221 | Molecular docking analysis of VEGF with compounds from tomato. | Bioinformation | 2022 | https://conductscience.org/library/papers/36945221 | PubMed |
| 36567417 | CPSF4 promotes tumor-initiating phenotype by enhancing VEGF/NRP2/TAZ signaling in lung cancer. | Med Oncol | 2022 | https://conductscience.org/library/papers/36567417 | PubMed |
| 36523304 | The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review. | Transl Cancer Res | 2022 | https://conductscience.org/library/papers/36523304 | PubMed |
| 36140220 | Inflammatory Cytokine: An Attractive Target for Cancer Treatment. | Biomedicines | 2022 | https://conductscience.org/library/papers/36140220 | PubMed |
| 36002195 | [Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated Advanced Non-small Cell Lung Cancer]. | Zhongguo Fei Ai Za Zhi | 2022 | https://conductscience.org/library/papers/36002195 | PubMed |
| 35813484 | VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment. | Int J Biol Sci | 2022 | https://conductscience.org/library/papers/35813484 | PubMed |
| 35743437 | Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis. | J Clin Med | 2022 | https://conductscience.org/library/papers/35743437 | PubMed |
| 35599308 | When to add anti-angiogenesis drugs to EGFR-mutated metastatic non-small cell lung cancer patients: a real-world study from Taiwan. | BMC Cancer | 2022 | https://conductscience.org/library/papers/35599308 | PubMed |
| 35116965 | Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma. | Transl Cancer Res | 2019 | https://conductscience.org/library/papers/35116965 | PubMed |
| 34855286 | Inhibitory effects of icotinib combined with antiangiogenic drugs in human non-small cell lung cancer xenograft models are better than single target drugs. | Thorac Cancer | 2022 | https://conductscience.org/library/papers/34855286 | PubMed |
| 34149898 | CXCR4 is a prognostic marker that inhibits the invasion and migration of gastric cancer by regulating VEGF expression. | Oncol Lett | 2021 | https://conductscience.org/library/papers/34149898 | PubMed |
| 33751366 | TRIPODD: a Novel Fluorescence Imaging Platform for In Situ Quantification of Drug Distribution and Therapeutic Response. | Mol Imaging Biol | 2021 | https://conductscience.org/library/papers/33751366 | PubMed |
| 33656275 | Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells. | Thorac Cancer | 2021 | https://conductscience.org/library/papers/33656275 | PubMed |
| 33506568 | ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non-small cell lung cancer. | Thorac Cancer | 2021 | https://conductscience.org/library/papers/33506568 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| EREG | 2069 | PubTator's text mining | https://conductscience.org/library/genes/2069 | NCBI Gene |
| KDR | 3791 | PubTator's text mining | https://conductscience.org/library/genes/3791 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25344762
GET https://conductscience.org/api/papers/v1/25344762/references?page=2